ArticleDigestive diseases and sciences2026
Abnormal MUC1 Expression as a Biomarker for Pouchitis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MUC1: Friend, Foe, or Bystander of Pouchitis?Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPouchitis is common among patients with ulcerative colitis (UC) and ileal-anal pouch anastomosis (IPAA). Healthy epithelial cells express low levels of the fully glycosylated MUC1 glycoprotein. In inflammation, MUC1 becomes overexpressed and hypoglycosylated, interfering with the mucus barrier and perpetuating inflammation. Our aim is to determine patterns of abnormal MUC1 expression in pouch mucosa of patients with UC after IPAA with varying degrees of pouchitis compared to mucosa from patients with familial adenomatous polyposis (FAP) with IPAA and no pouchitis.
methodsArchived biopsies of J-pouches were identified and stained to detect the abnormal hypoglycosylated MUC1. Each slide was graded for quantity and intensity of the abnormal MUC1 staining (both scored 0-4) by 3 team members blinded to the clinical information. Grading of inflammation was performed based on adaptation of the Nancy Histological Index. Data are expressed as median and interquartile range, and comparison was done through non-parametric tests to calculate p-value.
resultsTissue was analyzed from 4 FAP/IPAA (without pouchitis) and 87 patients with UC/IPAA and varying degrees of pouchitis; 19 no pouchitis, 27 mild, 36 moderate, and 5 severe pouchitis. There was almost no abnormal hypoglycosylated MUC1 expression among patients with no pouchitis, FAP, or UC. Patients with UC/IPAA had significantly more abnormal MUC1 expression in J-pouch ileal tissue that increased with the degree of pouchitis.
conclusionsAbnormal hypoglycosylated form of MUC1 in ileal biopsies of patients with UC and pouchitis was overexpressed and proportional to the degree of inflammation. Hypoglycosylated MUC1 may serve as a biomarker of more severe pouchitis.
Indexed as
Identifiers
41422478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.